BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33849399)

  • 1. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 5. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 6. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 7. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
    Bachireddy C; Terplan M
    Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pain Management Best Practices from Multispecialty Organizations During the COVID-19 Pandemic and Public Health Crises.
    Cohen SP; Baber ZB; Buvanendran A; McLean BC; Chen Y; Hooten WM; Laker SR; Wasan AD; Kennedy DJ; Sandbrink F; King SA; Fowler IM; Stojanovic MP; Hayek SM; Phillips CR
    Pain Med; 2020 Nov; 21(7):1331-1346. PubMed ID: 32259247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid Use Disorder and COVID-19: Crashing of the Crises.
    Khatri UG; Perrone J
    J Addict Med; 2020; 14(4):e6-e7. PubMed ID: 32404651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovations in efforts to expand treatment for opioid use disorder.
    Sigmon SC
    Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids: The Forgotten Epidemic?
    Price S
    Tex Med; 2020 Oct; 116(10):32-35. PubMed ID: 33126270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction).
    Suen LW; Incze M; Simon C; Englander H; Bratberg J; Groves Scott G; Winograd R
    Subst Use Addctn J; 2024 Jul; 45(3):337-345. PubMed ID: 38804606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19, mental health, and opioid use disorder: Old and new public health crises intertwine.
    Henry BF; Mandavia AD; Paschen-Wolff MM; Hunt T; Humensky JL; Wu E; Pincus HA; Nunes EV; Levin FR; El-Bassel N
    Psychol Trauma; 2020 Aug; 12(S1):S111-S112. PubMed ID: 32551759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
    Alexander K; Pogorzelska-Maziarz M; Gerolamo A; Hassen N; Kelly EL; Rising KL
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):60. PubMed ID: 34372900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for cannabis-based interventions in the opioid overdose crisis.
    Lucas P
    Harm Reduct J; 2017 Aug; 14(1):58. PubMed ID: 28821296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.